Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
I. Sougklakos
No relevant relationships to disclose
N. K. Vardakis
No relevant relationships to disclose
E. Kampouraki
No relevant relationships to disclose
I. Kotortsi
No relevant relationships to disclose
N. E. M. Androulakis
No relevant relationships to disclose
L. Vamvakas
No relevant relationships to disclose
K. Kalbakis
No relevant relationships to disclose
D. Hatzidaki
No relevant relationships to disclose
D. Mavroudis
No relevant relationships to disclose
V. Georgoulias
No relevant relationships to disclose